Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Backed By Full Pipeline To Battle Japan Price Controls And Slow U.S. Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

Tokyo-based firm reports net sales of ¥765.2 billion ($7.18 billion) for the 2008 third quarter compared to ¥702.5 billion ($6.59 billion) in the same quarter of 2007.

You may also be interested in...



Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients

Extended FDA review period up soon for long-lasting Prograf in liver transplant patients.

Astellas’ Once-Daily Tacrolimus Again “Approvable” For Kidney Transplant Patients

Extended FDA review period up soon for long-lasting Prograf in liver transplant patients.

Astellas Taps Pfizer Exec To Run New Global Development HQ

Long-time Pfizer exec Steven Ryder will become president of Astellas Pharma's new headquarters for global development in Deerfield, Ill., effective April 1, the Tokyo-based company announced March 4

Topics

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel